Contribute Try STAT+ Today

Watch: Merck’s Covid pill could transform treatment. Here’s how it works

Molnupiravir is the first oral treatment that has shown promise in treating Covid-19. Watch this short explainer to see how it works in the body to combat the coronavirus.

A likely new treatment for Covid-19 was made possible by government-funded innovation

Stronger government regulations should be in place to ensure that companies do not profit excessively from public funding or, at the very least, that some of the profits are plowed back into government funding for other innovative research.

What we know — and don’t know — about Merck’s new Covid-19 pill

STAT looks at the unanswered questions about Merck's new Covid-19 drug, molnupiravir, and about other Covid-fighting pills in development.

Merck’s antiviral pill reduces hospitalization of Covid patients, a possible game-changer for treatment

An investigational antiviral pill reduced the chances that patients newly diagnosed with Covid-19 would be hospitalized by about 50%.

Repurposing drugs can speed new treatments for Covid-19

Drug repurposing has saved lives during the pandemic. Veklury (the brand name for remdesivir) was originally developed to fight Ebola. Others are in the pipeline.

Pharmalittle: Pfizer CEO rallies employees to fight drug-price negotiations; Glaxo head pressured by another activist fund

GlaxoSmithKline CEO Emma Walmsley has come under pressure from a second activist hedge fund, which has taken a stake worth about $14 million to push for change at the top.

Remdesivir reduces Covid hospitalizations when given early, study shows

Gilead’s Covid-19 drug remdesivir appeared to reduce hospitalizations by 87% in high-risk patients diagnosed early in the disease in a new study, the company said.

For the first time, the FDA warns a trial investigator for failing to report study results

“While we applaud the FDA for appropriately enforcing federal statutes, it is regretful that it takes public accountability to drive compliance."

New antivirals are sorely needed. A public-private partnership can get us there

We need Covid-19 treatments delivered at home — orally if possible — that will reduce mild-to-moderate symptoms, shorten the length of illness and, most importantly, prevent hospitalization.

Pharmalittle: Biden pushes Congress to let Medicare negotiate drug prices; National Academies failed to disclose pharma-friendly committee ties

President Biden is calling on Congress to allow Medicare to negotiate prices of a subset of expensive medications.

Pharmalittle: Remdesivir props up Gilead’s declining fortunes; U.K. fines drug maker for price hikes

Sales of Gilead Sciences' remdesivir beat analysts' expectations in the second quarter, totaling $829 million.

Gene hunters turn up new clues to help explain why Covid-19 hits some people so hard

The international effort has revealed that an individual’s genetic inheritance can indeed influence their risk of infection and the severity of disease.

As Covid-19 rages in India, Gilead faces pressure to lower price of drug to treat black fungus in recovering patients

Gilead is facing pressure to lower the price of a drug to treat a rare and life-threatening infection.

Pharmalittle: Inside the FDA’s contentious Aduhelm approval; Peter Bach heading to liquid biopsy startup

Peter Bach, well-known as a drug pricing researcher and pharma industry gadfly, is leaving academia for an executive role at a biotech firm that aims to develop a blood test that can detect lung cancer.

Pervasive bias in algorithms, Pear’s SPAC, & an Amazon accelerator

A new report finds algorithms used in health care are rife with bias, and another new analysis finds a popular tool to predict sepsis may miss most cases.

Regeneron antibody saves lives in some hospitalized Covid patients, study finds

A monoclonal antibody treatment for Covid-19 developed by Regeneron saved lives among hospitalized patients who had not mounted their own immune response, researchers said in an important new finding.

Pharmalittle: FDA authorizes another Covid-19 treatment; judge indicates Purdue reorganization plan can be voted on

The FDA authorized a monoclonal antibody drug made by Vir Biotechnology and GlaxoSmithKline to treat early Covid-19 infections.

Pharmalittle: Vaccine makers urge Biden to end support of Covid-19 IP waiver; Russia accused of sowing doubt over Pfizer shot

Covid-19 vaccine makers have dialed up lobbying and public relations efforts to rally opposition to a proposal to temporarily waive their patents.

Pharmalittle: Sanofi and Glaxo tout positive Covid-19 vaccine results; Pfizer exec warns IP waiver will cause materials shortage

Sanofi and GlaxoSmithKline announced positive results from a Phase 2 clinical trial of their joint Covid-19 vaccine, saying it generated strong levels of neutralizing antibodies.

Pharmalittle: Novavax sees delay in seeking emergency use of its Covid-19 shot; AstraZeneca CEO’s pay causes a stink

AstraZeneca CEO Pascal Soriot is at the center of an extraordinary row among investors over his multi-million-dollar bonus.

Pharmalittle: Pfizer Covid-19 vaccine to generate $26 billion in 2021 sales; EMA reviews Sinovac Covid-19 vaccine

Pfizer now expects its Covid-19 vaccine to generate $26 billion in sales in 2021, up from an earlier forecast of $15 billion.

Gilead sues Russia over a compulsory license issued to a company making remdesivir

Amid worldwide clamoring for Covid-19 vaccines and other therapies, Gilead has filed a lawsuit against the Russian government for allowing a domestic company to manufacture and market remdesivir.

In Covid’s grip, India gasps for air: ‘If there is an apocalypse, this has to be one’

In India, ambulances are being crammed with the dead on their way to crematoria and burial grounds. Funeral pyres glowing 24/7 are a constant reminder of the staggering death toll. If there is an apocalypse, this has to be one.

Pharmalittle: What will Biden say about drug pricing? U.S. trade rep meets with drug makers over WTO proposal

This is the eve of a major speech by President Biden, but it’s anyone’s guess what he will say about drug pricing.

Pharmalittle: Europe looks to sue AstraZeneca over Covid-19 vaccine shortfalls; FDA skewers Emergent vaccine facility

The European Commission is getting ready to launch legal proceedings against Covid-19 vaccine producer AstraZeneca over complaints it failed to deliver pledged doses.

Pharmalittle: Pfizer identifies first counterfeit versions of its Covid-19 vaccine; top house Democrats investigate Emergent BioSolutions

Pfizer says it has identified in Mexico and Poland the first confirmed counterfeit versions of the Covid-19 vaccine it developed with BioNTech.

Pharmalittle: J&J denies design of its Covid-19 shot may explain blood clots; second trial against opioid makers begins

Scientists at J&J refuted an assertion that the design of its Covid-19 vaccine, which is similar to the AstraZeneca shot, may explain why both have been linked to very rare blood clots.

Pharmalittle: Pause for J&J Covid-19 shot to continue at least a week; Biden expands candidate list for FDA commish

The U.S. government pause on use of the Johnson & Johnson Covid-19 vaccine is unlikely to be lifted for at least another week or 10 days.

Pharmalittle: U.S. urges states to pause J&J Covid-19 shots; PhRMA’s new message says ‘Don’t take us for granted’

U.S. authorities recommended that states stop using the Johnson & Johnson Covid-19 vaccine while an investigation is conducted into six rare but serious cases of clotting problems in women.